189 related articles for article (PubMed ID: 26020272)
21. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
[TBL] [Abstract][Full Text] [Related]
23. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
24. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
25. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
[TBL] [Abstract][Full Text] [Related]
26. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Liang JG; Jin ZY; Gao XD; Te MR; Ge LH; Wang CL
Genet Mol Res; 2014 Jul; 13(3):5292-8. PubMed ID: 25078585
[TBL] [Abstract][Full Text] [Related]
27. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
[TBL] [Abstract][Full Text] [Related]
28. Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Dongiovanni D; Fissore C; Berruti A; Buffoni L; Addeo A; Barone C; Polimeni MA; Ottaviani D; Bertetto O; Dongiovanni V
Lung Cancer; 2005 Feb; 47(2):269-75. PubMed ID: 15639726
[TBL] [Abstract][Full Text] [Related]
29. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
30. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
[TBL] [Abstract][Full Text] [Related]
31. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Rosell R; Scagliotti G; Danenberg KD; Lord RV; Bepler G; Novello S; Cooc J; Crinò L; Sánchez JJ; Taron M; Boni C; De Marinis F; Tonato M; Marangolo M; Gozzelino F; Di Costanzo F; Rinaldi M; Salonga D; Stephens C
Oncogene; 2003 Jun; 22(23):3548-53. PubMed ID: 12789263
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Fournel P
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S42-7. PubMed ID: 12538935
[No Abstract] [Full Text] [Related]
33. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
36. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
Rosati G; Rossi A; Nicolella G; Panza N
Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183
[TBL] [Abstract][Full Text] [Related]
37. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Brunetto AT; Carden CP; Myerson J; Faria AL; Ashley S; Popat S; O'Brien ME
J Thorac Oncol; 2010 Sep; 5(9):1397-403. PubMed ID: 20644495
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
[TBL] [Abstract][Full Text] [Related]
39. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
